{"sentence": "Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.", "spans": [[14, 21], [39, 46], [75, 82]], "date": "2022-03-30T13:00:00+00:00", "span_values": ["viatris", "Twitter"]}
{"sentence": "Let's look at two stocks income-seeking investors would do well to buy at current levels: Merck (NYSE: MRK) and Viatris (NASDAQ: VTRS).", "spans": [[90, 95], [112, 119]], "date": "2022-03-29T15:00:00+00:00", "span_values": ["Merck", "Viatris"]}
{"sentence": "Viatris is an unloved global pharmaceutical manufacturer created through the merger of Mylan and Upjohn (Pfizer’s off-patent drugs business).", "spans": [[0, 7], [105, 111]], "date": "2022-03-21T12:55:47+00:00", "span_values": ["Pfizer", "Viatris"]}
{"sentence": "Representative holdings in the Fund include Cigna, United Health Group, Viatris and Quest Diagnostics.", "spans": [[44, 49], [72, 79], [84, 101]], "date": "2022-03-21T12:46:22+00:00", "span_values": ["Viatris", "Cigna", "Quest Diagnostics"]}
{"sentence": "Canonsburg-based pharmaceutical company Viatris Inc. said it prevailed in federal court against Biogen over a patent for a drug that had been launched as a generic in August 2020.", "spans": [[40, 47], [96, 102]], "date": "2022-03-17T20:50:13+00:00", "span_values": ["Viatris", "Biogen"]}
{"sentence": "Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent.", "spans": [[0, 7], [16, 22]], "date": "2022-03-17T18:54:00+00:00", "span_values": ["Viatris", "Biogen"]}
{"sentence": "Federal Circuit Refuses to Reconsider Decision Invalidating Biogen's Patent Covering its Multiple Sclerosis Product Tecfidera®PITTSBURGH, March 17, 2022 /PRNewswire/ -- Viatris Inc.", "spans": [[60, 66], [169, 176]], "date": "2022-03-17T18:54:00+00:00", "span_values": ["Viatris", "Biogen"]}
{"sentence": "Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.", "spans": [[14, 21], [39, 46], [75, 82]], "date": "2022-03-17T18:54:00+00:00", "span_values": ["viatris", "Twitter"]}
{"sentence": "Factors that could cause or contribute to such differences include, but are not limited to: the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; that the pending transaction between Viatris and Biocon Biologics Limited, pursuant to which Viatris will contribute its biosimilar products and programs to Biocon Biologics in exchange for cash consideration and a convertible preferred equity interest in Biocon Biologics, may not achieve its intended benefits; the integration of Mylan N.V. and Pfizer Inc.'s Upjohn business (the \"Upjohn Business\"), which combined to form Viatris (the \"Combination\") and the implementation of our global restructuring initiatives being more difficult, time consuming or costly than expected, or being unsuccessful; the ability to achieve expected benefits, synergies, and operating efficiencies in connection with the Combination or its restructuring initiatives within the expected timeframe or at all; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to \"at-risk\" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC).", "spans": [[286, 293], [342, 349], [596, 602], [674, 681], [1238, 1245], [1337, 1344], [1841, 1848], [2017, 2024], [2135, 2142]], "date": "2022-03-17T18:54:00+00:00", "span_values": ["Pfizer", "Viatris"]}
{"sentence": "Thirty-five generic drugmakers will produce low-cost versions of Pfizer Inc's (NYSE: PFE) COVID-19 pill, Paxlovid, to expand supplies of the highly effective drug in lower-income regions.", "spans": [[65, 71], [179, 186]], "date": "2022-03-17T18:19:36+00:00", "span_values": ["Pfizer", "regions"]}
{"sentence": "See more from BenzingaAlnylam Hits Pfizer, Moderna With Patent Infringement Suits WHO Foundation Warns Global Economy To Lose \"Trillions Of Dollars\" On COVID-19 Vaccine Inequality: CNBCDon't miss real-time alerts on your stocks - join Benzinga Pro for free!", "spans": [[35, 41], [43, 50]], "date": "2022-03-17T18:19:36+00:00", "span_values": ["Moderna", "Pfizer"]}
{"sentence": "Big corporations including Amazon and Meta Platforms (formerly Facebook) have also sought to weaken Lina Kahn, chair of the Federal Trade Commission, who is overseeing FTC investigations of their operations.", "spans": [[27, 33], [38, 42]], "date": "2022-03-16T18:53:01+00:00", "span_values": ["Meta", "Amazon"]}
{"sentence": "Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.", "spans": [[14, 21], [39, 46], [75, 82]], "date": "2022-03-16T11:30:00+00:00", "span_values": ["viatris", "Twitter"]}
{"sentence": "Factors that could cause or contribute to such differences include, but are not limited to: the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; the pending transaction between Viatris and Biocon Biologics Limited, pursuant to which Viatris will contribute its biosimilar products and programs to Biocon Biologics in exchange for cash consideration and a convertible preferred equity interest in Biocon Biologics, may not achieve its intended benefits; the integration of Mylan N.V. and Pfizer Inc.'s Upjohn business (the \"Upjohn Business\"), which combined to form Viatris (the \"Combination\") and the implementation of our global restructuring initiatives being more difficult, time consuming or costly than expected, or being unsuccessful; the ability to achieve expected benefits, synergies, and operating efficiencies in connection with the Combination or its restructuring initiatives within the expected timeframe or at all; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to \"at-risk\" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC).", "spans": [[281, 288], [337, 344], [591, 597], [669, 676], [1233, 1240], [1332, 1339], [1836, 1843], [2012, 2019], [2130, 2137]], "date": "2022-03-16T11:30:00+00:00", "span_values": ["Pfizer", "Viatris"]}
{"sentence": "We note that Viatris was formed in November 2020 through the combination of Mylan and Pfizer’s PFE Upjohn.", "spans": [[13, 20], [86, 92]], "date": "2022-03-11T19:21:07+00:00", "span_values": ["Pfizer", "Viatris"]}
{"sentence": "So, as Viatris and other generic drug makers plunge, what should you buy instead?8 Strong Uptrend Stocks to Buy on the Next DipConsider these seven well-known drug stocks, all of which are good value in what’s still a pricey market:AbbVie (NYSE:ABBV) Bristol-Myers Squibb (NYSE:BMY) GlaxoSmithKline (NYSE:GSK) Johnson & Johnson (NYSE:JNJ) Merck (NYSE:MRK) Novartis (NYSE:NVS) Pfizer (NYSE:PFE)Drug", "spans": [[7, 14], [232, 238], [310, 327], [339, 344], [376, 382]], "date": "2022-03-10T12:35:12+00:00", "span_values": ["Pfizer", "Johnson & Johnson", "Merck", "AbbVie", "Viatris"]}
{"sentence": "Source: Manuel Esteban / Shutterstock.comCapping things off, let’s look at shares in the company that spun-off Viatris: Pfizer.", "spans": [[111, 118], [120, 126]], "date": "2022-03-10T12:35:12+00:00", "span_values": ["Pfizer", "Viatris"]}
{"sentence": "Alvotech will be allowed to market AVT02 beginning July 1, 2023, making it the third adalimumab biosimilar to enter the U.S. market, following Amgen Inc’s (NASDAQ: AMGN) Amjevita, which is expected to launch in January 2023, and Organon & Co (NYSE: OGN) and Samsung Bioepis’ Hadlima, expected to launch in July 2023.", "spans": [[143, 148], [229, 236]], "date": "2022-03-09T13:25:51+00:00", "span_values": ["Organon", "Amgen"]}
{"sentence": "Shares of Viatris (NASDAQ: VTRS) fell 24.4% in February, according to data provided by S&P Global Market Intelligence.", "spans": [[10, 17], [87, 97]], "date": "2022-03-08T21:51:37+00:00", "span_values": ["S&P Global", "Viatris"]}
{"sentence": "2021 was Viatris' first full year as a unified entity -- a company formed by the spinoff and merger of Pfizer's generic drug division with another generic maker called Mylan.", "spans": [[9, 16], [103, 109]], "date": "2022-03-04T16:23:00+00:00", "span_values": ["Pfizer", "Viatris"]}
{"sentence": "Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.", "spans": [[14, 21], [39, 46], [75, 82]], "date": "2022-03-01T21:30:00+00:00", "span_values": ["viatris", "Twitter"]}
{"sentence": "Viatris Inc. -- Moody's: Viatris' biosimilars transaction is credit positive but tempered by core earnings pressure and ongoing cash outlays.", "spans": [[0, 7], [16, 23], [25, 32]], "date": "2022-03-01T00:52:06+00:00", "span_values": ["Viatris", "Moody's"]}
{"sentence": "Announcement: Moody's: Viatris' biosimilars transaction is credit positive but tempered by core earnings pressure and ongoing cash outlaysGlobal Credit Research - 28 Feb 2022New York, February 28, 2022 -- Moody's Investors Service commented that Viatris Inc.'s formation of a biosimilars partnership with Biocon Limited is credit positive for Viatris, based on a substantial cash inflow of $2 billion that will facilitate debt reduction.", "spans": [[14, 21], [23, 30], [205, 212], [246, 253], [343, 350]], "date": "2022-03-01T00:52:06+00:00", "span_values": ["Viatris", "Moody's"]}
{"sentence": "For additional information please see Moody's Issuer Comment on Viatris Inc. available on www.moodys.com.", "spans": [[38, 45], [64, 71]], "date": "2022-03-01T00:52:06+00:00", "span_values": ["Viatris", "Moody's"]}
{"sentence": "Some stocks on the move today include Etsy Inc (NASDAQ:ETSY), Philip Morris International Inc. (NYSE:PM), and United Airlines Holdings, Inc. (NASDAQ:UAL).Let’s discuss why each stock is moving and how elite funds were positioned among them.", "spans": [[38, 42], [55, 59], [62, 89], [110, 125]], "date": "2022-02-28T19:48:38+00:00", "span_values": ["Philip Morris International", "ETSY", "Etsy", "United Airlines"]}
{"sentence": "Harris Associates owned over 28 million shares in Citigroup Inc. (NYSE:C) at the end of Q4.8. L3Harris", "spans": [[50, 59], [94, 102]], "date": "2022-02-28T19:48:38+00:00", "span_values": ["L3Harris", "Citigroup"]}
{"sentence": "APA Corporation (NASDAQ:APA) rallied 5.41% to $35.51 on Monday following the company’s recent offshore oil and gas discovery in Krabdagu.", "spans": [[0, 15], [115, 124]], "date": "2022-02-28T19:48:38+00:00", "span_values": ["discovery", "APA Corporation"]}
{"sentence": "Like APA Corporation (NASDAQ:APA), Etsy Inc (NASDAQ:ETSY), Philip Morris International Inc. (NYSE:PM), and United Airlines Holdings, Inc. (NASDAQ:UAL) are also on the move.", "spans": [[5, 20], [35, 39], [52, 56], [59, 86], [107, 122]], "date": "2022-02-28T19:48:38+00:00", "span_values": ["ETSY", "United Airlines", "Philip Morris International", "Etsy", "APA Corporation"]}
{"sentence": "Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd. for up to $3.335 billion.", "spans": [[0, 7], [61, 67]], "date": "2022-02-28T11:23:26+00:00", "span_values": ["Pfizer", "Viatris"]}
